Efficacy of a Primary Chemotherapy Regimen Combining Vinorelbine, Epirubicin, and Methotrexate (VEM) as Neoadjuvant Treatment in 89 Patients with Operable Breast Cancer

Purpose. In order to improve the breast conservation rate for noninflammatory operable breast cancer stage II and IIIa, neoadjuvant chemotherapy containing vinorelbine, 25 mg/m2, epirubicin, 35 mg/m2, and methotrexate, 20 mg/m2, VEM, was administered days 1 and 8 every 28 days for six cycles. Methods. From October, 1991 to April, 1996, 89 patients (median age 52 years, range 31‐72; 68 stage II and 19 stage IIIa) received 519 cycles (median six) of VEM chemotherapy. Results. Hematotoxicity was mild (World Health Organization grade 3‐4 neutropenia in 28% of cycles for 22 patients, and anemia or thrombocytopenia >grade 2) when it occurred, and there were no toxic deaths. The clinical objective response was 90% (28% complete response and 62% partial response). All patients underwent surgery: 77 (87%) had conservative and 12 (13%) had modified radical mastectomy, and 12 (14%) reached pathological complete response. At December, 2000, with a median follow‐up of 86 months (39‐100), 13 patients had relapsed, and five had died of metastatic disease. Median disease‐free survival was 100 months (8.4 years) and median survival had not yet been reached.